by Xcellerant Ventures | Apr 29, 2025 | Portfolio Company News
BIOTECH: Co. Shifting to Commercialization with Recent Capital Funding SAN DIEGO – While research and development of gene editing-based therapies has exploded across the biotech industry in recent years, many companies still lack a process to prevent bad chemical...
by Xcellerant Ventures | Aug 12, 2024 | Portfolio Company News
Origionally posted on EIN Presswire: https://www.einpresswire.com/article/710284206/lenoss-medical-oversubscribes-4-million-series-a-financing SAN DIEGO–(BUSINESS WIRE)–CRISPR QC, a pioneering biotechnology company in San Diego, is excited to...
by Xcellerant Ventures | Jul 27, 2024 | Portfolio Company News
Origionally posted on CRISPR QC’s website: https://crisprqc.com/wp-content/uploads/2024/08/20240806-CRISPR-Cleave-Case-Study-Layout.pdf Key Takeaways: CRISPR QC’s in vitro CRISPR-Cas cleavage assays can streamline CRISPR workflows by identifying optimal...
by Xcellerant Ventures | Jul 26, 2024 | Portfolio Company News
Origionally posted on CRISPR QC’s website: https://crisprqc.com/wp-content/uploads/2024/08/20240806-CRISPR-RNP-Case-Study-Layout.pdf Key Takeaways: A critical gap exists in the CRISPR workflow: the lack of an in vitro QC step. The CRISPR Analytics...
by Xcellerant Ventures | Jul 25, 2024 | Portfolio Company News
Origionally posted on CRISPR QC’s website: https://crisprqc.com/wp-content/uploads/2024/08/20240806-CRISPR-DNA-Case-Study-Layout.pdf Key Takeaways: The CRISPR Analytics Platform is an in vitro tool for measuring CRISPR editing efficiency, as well as, RNP...
